CNBC’s Angelica Peebles and Novo Nordisk CEO Lars Fruergaard Jørgensen join 'Squawk Box' to discuss the company's quarterly ...

Danish drugmaker Novo Nordisk reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's ...

Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in the company's latest obesity drug offering, including its new oral weight loss candidate.

The chip maker posted a big jump in revenue in its data-center business, but the results undershot analysts' r ...

In the pharmaceuticals sector, Novo Nordisk is due to report ... Inside Out 2 and Marvel's Deadpool & Wolverine "broke numerous box office records and helped drive $316m in operating income ...

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight ...

And one effect of semaglutide, as we all know now, has been the box-office draw from day one ... In 2018, the world learned Novo Nordisk’s name when the company released semaglutide as Ozempic.

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're about to lose access.

The Nasdaq and other major stock market indexes dipped Wednesday after underwhelming earnings reports from Google parent ...

Follow along for live updates on stocks, bonds and markets, including the Dow Jones Industrial Average, S&P 500 and Nasdaq Composite.

As we mentioned on Tuesday, the majority of companies on the S&P 500 that have reported earnings, have beaten estimates, and ...